SG135193A1 - Dosing schedule for erbb2 anticancer agents - Google Patents

Dosing schedule for erbb2 anticancer agents

Info

Publication number
SG135193A1
SG135193A1 SG200706063-5A SG2007060635A SG135193A1 SG 135193 A1 SG135193 A1 SG 135193A1 SG 2007060635 A SG2007060635 A SG 2007060635A SG 135193 A1 SG135193 A1 SG 135193A1
Authority
SG
Singapore
Prior art keywords
erbb2
mammal
directed
inhibitor
anticancer agents
Prior art date
Application number
SG200706063-5A
Other languages
English (en)
Inventor
Samit Kumar Bhattacharya
Richard Damian Connell
James Dale Moyer
Jitesh Pranlal Jani
Dennis Alan Noe
Stefanus Johannes Steyn
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of SG135193A1 publication Critical patent/SG135193A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG200706063-5A 2003-08-18 2004-08-06 Dosing schedule for erbb2 anticancer agents SG135193A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49591903P 2003-08-18 2003-08-18

Publications (1)

Publication Number Publication Date
SG135193A1 true SG135193A1 (en) 2007-09-28

Family

ID=34193358

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200706063-5A SG135193A1 (en) 2003-08-18 2004-08-06 Dosing schedule for erbb2 anticancer agents

Country Status (18)

Country Link
US (1) US20050119288A1 (OSRAM)
EP (1) EP1658080A1 (OSRAM)
JP (1) JP2007502807A (OSRAM)
KR (2) KR20060037447A (OSRAM)
CN (1) CN1838959A (OSRAM)
AR (1) AR045268A1 (OSRAM)
AU (1) AU2004264726A1 (OSRAM)
BR (1) BRPI0413745A (OSRAM)
CA (1) CA2536140A1 (OSRAM)
CO (1) CO5670356A2 (OSRAM)
IL (1) IL173127A0 (OSRAM)
MX (1) MXPA06001989A (OSRAM)
NO (1) NO20061252L (OSRAM)
RU (1) RU2328287C2 (OSRAM)
SG (1) SG135193A1 (OSRAM)
TW (1) TW200522966A (OSRAM)
WO (1) WO2005016347A1 (OSRAM)
ZA (1) ZA200600517B (OSRAM)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101717410B (zh) 2002-02-01 2015-04-29 阿里亚德医药股份有限公司 含磷化合物及其应用
TWI229650B (en) * 2002-11-19 2005-03-21 Sharp Kk Substrate accommodating tray
NZ545459A (en) * 2003-08-14 2009-12-24 Array Biopharma Inc Quinazoline analogs as receptor tyrosine kinase inhibitors
US7501427B2 (en) * 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
PL1667992T3 (pl) 2003-09-19 2007-05-31 Astrazeneca Ab Pochodne chinazoliny
RS52119B (sr) 2004-05-06 2012-08-31 Warner-Lambert Company Llc 4-fenilamino-hinazolin-6-il-amidi
GB0427131D0 (en) * 2004-12-10 2005-01-12 Glaxosmithkline Biolog Sa Novel combination
JP2008542354A (ja) * 2005-06-03 2008-11-27 ファイザー・プロダクツ・インク 癌治療におけるｅｒｂＢ２阻害剤と他の治療薬の併用
JP5235662B2 (ja) * 2005-06-16 2013-07-10 ミリアド ジェネティクス， インコーポレイテッド 薬学的組成物およびその使用
US20080219977A1 (en) * 2005-07-27 2008-09-11 Isaiah Josh Fidler Combinations Comprising Gemcitabine and Tyrosine Kinase Inhibitors for the Treatment of Pancreatic Cancer
US8945573B2 (en) 2005-09-08 2015-02-03 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Targeted identification of immunogenic peptides
CN101360495B (zh) * 2005-11-14 2012-03-14 阿里亚德医药股份有限公司 对癌症病人给药mTOR抑制剂
DE602006009968D1 (de) 2005-11-15 2009-12-03 Array Biopharma Inc N4-phenyl-chinazolin-4-aminderivate und verwandte verbindungen als inhibitoren der erbb-typ-i-rezeptortyrosinkinase zur behandlung hyperproliferativer krankheiten
CN101484807A (zh) * 2006-03-31 2009-07-15 麻省理工学院 表达突变型egf受体的肿瘤的治疗
JP2009532497A (ja) * 2006-04-05 2009-09-10 ノバルティス アクチエンゲゼルシャフト 癌を処置するための治療剤の組合せ
JP2010509400A (ja) 2006-11-14 2010-03-25 アリアド・ファーマシューティカルズ・インコーポレイテッド 経口処方組成物
AU2008236997A1 (en) * 2007-04-10 2008-10-16 Myrexis, Inc. Methods for treating cancer
AU2008236993A1 (en) * 2007-04-10 2008-10-16 Myrexis, Inc. Method of treating brain cancer
WO2008124828A1 (en) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Methods for treating vascular disruption disorders
WO2008124824A1 (en) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Dosages and methods for the treatment of cancer
EP2144886A4 (en) * 2007-04-10 2012-10-03 Myrexis Inc METHOD OF TREATING MELANOMA
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
CA3006428A1 (en) 2007-06-08 2008-12-18 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
US8252805B2 (en) * 2008-05-07 2012-08-28 Teva Pharmaceutical Industries Ltd. Forms of lapatinib ditosylate and processes for preparation thereof
WO2010027848A2 (en) * 2008-08-26 2010-03-11 Teva Pharmaceutical Industries Ltd. Forms of lapatinib compounds and processes for the preparation thereof
AR075896A1 (es) * 2009-03-20 2011-05-04 Genentech Inc Anticuerpos anti-her (factor de crecimiento epidermico)
EP2793893A4 (en) * 2011-11-23 2015-07-08 Intellikine Llc IMPROVED TREATMENT REGIMES USING MTOR INHIBITORS
EP3101115B1 (en) 2014-01-31 2020-10-21 Toppan Printing Co., Ltd. Biomolecule analysis kit and biomolecule analysis method
CN108473538B (zh) * 2015-10-28 2022-01-28 塔弗达治疗有限公司 Sstr靶向缀合物及其颗粒和制剂

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA932522B (en) * 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
CA2216796C (en) * 1995-03-30 2003-09-02 Pfizer Inc. Quinazoline derivatives
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
JP4044839B2 (ja) * 2000-06-22 2008-02-06 ファイザー・プロダクツ・インク 異常細胞増殖を治療するための置換２環式誘導体
AU2002339687A1 (en) * 2001-12-12 2003-06-23 Pfizer Products Inc. Quinazoline derivatives for the treatement of abnormal cell growth
HRP20040530A2 (en) * 2001-12-12 2004-10-31 Pfizer Prod Inc Salt forms of e-2-methoxy-n-(3-(4-(3-methyl-pyridin-3-yloxy)-phenylamino)-quinazolin-6-yl)-allyl)-acetamide, its preparation and its use against cancer
JP4611745B2 (ja) * 2002-11-20 2011-01-12 アレイ バイオファーマ、インコーポレイテッド ＥｒｂＢ２及びＥＧＦＲ阻害剤としてのシアノグアニジン及びシアノアミジン
RU2005119172A (ru) * 2002-12-18 2006-01-20 Пфайзер Продактс Инк. (Us) Производные 4-анилинхиназолина для лечения патологического роста клеток

Also Published As

Publication number Publication date
KR20080014144A (ko) 2008-02-13
TW200522966A (en) 2005-07-16
CA2536140A1 (en) 2005-02-24
CN1838959A (zh) 2006-09-27
WO2005016347A1 (en) 2005-02-24
IL173127A0 (en) 2006-06-11
US20050119288A1 (en) 2005-06-02
AR045268A1 (es) 2005-10-19
AU2004264726A1 (en) 2005-02-24
ZA200600517B (en) 2007-02-28
RU2006102125A (ru) 2007-09-27
BRPI0413745A (pt) 2006-10-24
EP1658080A1 (en) 2006-05-24
CO5670356A2 (es) 2006-08-31
MXPA06001989A (es) 2006-05-17
RU2328287C2 (ru) 2008-07-10
JP2007502807A (ja) 2007-02-15
NO20061252L (no) 2006-05-16
KR20060037447A (ko) 2006-05-03

Similar Documents

Publication Publication Date Title
SG135193A1 (en) Dosing schedule for erbb2 anticancer agents
MX2024004444A (es) Compuestos de quinolina como inhibidores de la proteina del virus de sarcoma de rata kirsten (kras).
CR20240059A (es) Compuestos tricíclicos como inhibidores de kras.
MXPA05003501A (es) Metodos para tratamiento del dolor administrando un antagonista del factor de crecimiento del nervio y un analgesico opioide y composiciones que los contienen.
WO2004043374A3 (en) Methods and compositions for treating cancer using proteasome inhibitors
GEP20033140B (en) Substituted Bicyclic Derivatives Useful as Anticancer Agents
AU2483000A (en) Treatment of asthma with mek inhibitors
GEP20053424B (en) Pyrimidine-2,4,6-Trione Metalloproteinase Inhibitors
MX2011007854A (es) Metodos para tratar infartos agudos al miocardio y trastornos relacionados.
TW200806299A (en) Treatment of pain
TR199900827T2 (xx) Siklooksigenaz-2 inhibit�rlerinin neoplazinin tedavisinde ve �nlenmesinde kullan�m�.
SI1530469T1 (sl) Transdermalna odmerna oblika, ki obsega aktivno sredstvo in antagonist v obliki soli in v obliki proste baze
MX2025012306A (es) Inhibidores del gen de sarcoma de rata de kirsten (kras) de 2-azabiciclo [2.2.1] heptano
WO2004004661A3 (en) Boroproline compound combination therapy
WO2004045593A3 (en) Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
PL1664016T3 (pl) Środki terapeutyczne przydatne do leczenia bólu
MY125490A (en) Method of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction
AU2009246603A8 (en) Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction
TW200639159A (en) Treatment of pain
CA2235412A1 (en) Pharmaceutical composition containing an activin or inhibin stimulator
IL165259A (en) Compounds useful in the treatment of anthrax and inhibiting lethal factor
MX2020007817A (es) Prevención y tratamiento del trastorno del sueño.
WO2001080813A3 (en) Methods for preventing and treating alopecia induced by chemotherapy or radiotherapy
TW200503666A (en) Treatment of type 1 diabetes with pde5 inhibitors
DE60325965D1 (de) Für die behandlung bzw. prevention von schmerzen geeignete triazaspiroverbindungen